Infusion reactions to the chimeric EGFR inhibitor cetuximab-change to the fully human anti-EGFR monoclonal antibody panitumumab is safe

Annals of Oncology

Volumn 22, Issue 2, 2011, Pages 486-487

  Resch, G ^a   Schaberl Moser, R ^b   Kier, P ^c   Kopetzky, G ^d   Scheithauer, W ^e   Sliwa, T ^f   Greil, R ^g   Nosslinger T ^h   Mayrbaurl B ^a   Thaler, J ^a  

^a Klinikum Wels Grieskirchen GmbH   (Austria)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

^c DANUBE HOSPITAL   (Austria)

^d Hospital St Pölten   (Austria)

^e MEDICAL UNIVERSITY OF VIENNA   (Austria)

^f Hietzing Hospital   (Austria)

^g PARACELSUS MEDICAL UNIVERSITY   (Austria)

^h HANUSCH HOSPITAL   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; PANITUMUMAB;

ANTIGEN ANTIBODY REACTION; BRONCHOSPASM; CANCER CHEMOTHERAPY; CHIMERA; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; HEART ARREST; HUMAN; HYPOTENSION; IMMUNOGENICITY; LETTER; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; STRIDOR; URTICARIA;

EID: 79251569271     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq744     Document Type: Letter

References (10)

1. Nielsen DL, Pfeiffer P, Jensen BV. Six cases of treatment with panitumumab in patients with severe hypersensitivity reactions to Cetuximab. Ann Oncol 2009; 20(4): 798.
2. Helbling D, Borner M. Successful challenge with the fully human EGFR antibody panitumumab following an infusion reaction with the chimeric EGFR antibody Cetuximab. Ann Oncol 2007; 18(5): 963-964.
3. Resch G, Schaberl-Moser R, Kier P et al. Analysis of the Austrian compassionate use program of panitumumab in patients with metastatic colorectal cancer. ASCO GI, 2009, Abstract 428.
4. ImClone Systems Incorporated, Bristol-Myers Squibb. Erbitux (Cetuximab) package insert. New York, NY, and Princeton NJ 2006.
5. Saltz LB, Meropol NJ, Loehrer PJ Sr et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22: 1201-1208.
6. Peeters M, Cutsem V, Berlin J et al. Safety of panitumumab, a fully human monoclonal antibody against the epidermal growth factor receptor, in patients with metastatic colorectal cancer across clinical trials. J Clin Oncol 2007; 25: 413.
7. Foley KA, Wang PF, Barber BL et al. Clinical and economic impact of infusion reactions in patients with colorectal cancer treated with Cetuximab. Ann Oncol 2010; 21: 1455-1461.
8. Van Cutsem E, Siena S, Humblet Y et al. An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy. Ann Oncol 2008; 19(1): 92-98.
9. VectibixTM (panitumumab) [package insert]. Minervum, the Netherlands: Amgen Europe B.V.
10. Peeters M, Cutsem V, Berlin J et al. Safety of panitumumab, a fully human monoclonal antibody against the epidermal growth factor receptor, in patients with metastatic colorectal cancer across clinical trials. J Clin Oncol 2007; 25: 413.